Incidence of milk alkali syndrome in the Women's Health Initiative clinical trial and cohort study

Osteoporosis International

Volumn 25, Issue 3, 2014, Pages 1193-

  Neupane, S ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DENSITY CONSERVATION AGENT; CALCIUM CARBONATE; COLECALCIFEROL;

ADVERSE EFFECTS; DIET SUPPLEMENTATION; FEMALE; HUMAN; OSTEOPOROTIC FRACTURES;

BONE DENSITY CONSERVATION AGENTS; CALCIUM CARBONATE; CHOLECALCIFEROL; DIETARY SUPPLEMENTS; FEMALE; HUMANS; OSTEOPOROTIC FRACTURES;

EID: 84894589570     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2451-1     Document Type: Letter

References (3)

1. Picolos MK, Lavis VR, Orlander PR (2005) Milk alkali syndrome is a major cause of hypercalcemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 63(5):566-576
2. Felsenfeld AJ, Levine BS (2006) Milk alkali syndrome and the dynamics of calcium homeostasis. CJASN 1(4):641-654
3. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, LaCroix JA, Anderson GL, Chlebowski RT, Manson E, Van Horn L, Vitolins MJ, Datta M, LeBlanc ES, Cauley JA, Rossouw JE (2013) Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int 24(2):567-580